8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Dec 16, 2025·SEC
Surgery Partners, Inc.(SGRY)Earnings, Financials & Key Ratios
SGRY•NASDAQ
Price updated Jun 19, 2026
AboutSurgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.Show more
- Revenue$3.31B+6.2%
- EBITDA$566M+12.8%
- Net Income-$78M+53.7%
- EPS (Diluted)-0.61+54.1%
- Gross Margin23.12%-3.4%
- EBITDA Margin17.09%+6.2%
- Operating Margin11.77%+5.1%
- Net Margin-2.35%+56.4%
- ROE-2.18%+54.7%
SGRY Key Insights
Surgery Partners, Inc. (SGRY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 12.2%
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SGRY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SGRY Price & Volume
Surgery Partners, Inc. (SGRY) stock price & volume — 10-year historical chart
Loading chart...
SGRY Growth Metrics
Surgery Partners, Inc. (SGRY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.17%
5 Years12.21%
3 Years9.22%
TTM5.38%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM60.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM61.46%
Return on Capital
10 Years5.28%
5 Years5.45%
3 Years5.19%
Last Year5.23%
SGRY Recent Earnings
Surgery Partners, Inc. (SGRY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.03+80.0%
$0.15
Rev
$811M+1.7%
$798M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.12-61.3%
$0.31
Rev
$885M+2.1%
$867M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.13-31.6%
$0.19
Rev
$822M-5.2%
$867M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.17+6.3%
$0.16
Rev
$826M+0.3%
$824M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.03vs $0.15+80.0% | $811Mvs $798M+1.7% |
| Q2 2026 | Mar 2, 2026 | $0.12vs $0.31-61.3% | $885Mvs $867M+2.1% |
| Q4 2025 | Nov 10, 2025 | $0.13vs $0.19-31.6% | $822Mvs $867M-5.2% |
| Q3 2025 | Aug 5, 2025 | $0.17vs $0.16+6.3% | $826Mvs $824M+0.3% |
Based on last 12 quarters of dataView full earnings history →
SGRY Peer Comparison
Surgery Partners, Inc. (SGRY) competitors in Outpatient clinics and surgery centers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 USPH | 964.39M | 63.32 | 44.59 | 16.33% | 1.52% | 1.36% | 0.55 | |
 SEM | 2.05B | 16.54 | 14.02 | 5.12% | 2.42% | 6.57% | 1.82 | |
 AMSF | 588.66M | 31.32 | 12.68 | 2.63% | 14.27% | 9.68% | 0.00 | |
 NHC | 3.15B | 201.53 | 26.28 | 16.38% | 8.11% | 11.63% | 0.08 | |
 ADUS | 1.76B | 94.23 | 18.09 | 23.21% | 6.89% | 9.34% | 0.19 | |
 ALHC | 4.47B | 21.86 | -5908.11 | 46.06% | 0.47% | 11.5% | 1.89 | |
 UHS | 8.84B | 141.17 | 6.11 | 9.71% | 8.56% | 20.65% | 0.74 | |
 HCA | 83.88B | 375.17 | 13.22 | 7.08% | 8.97% |
Compare SGRY vs Peers
Surgery Partners, Inc. (SGRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SGRY Income Statement
Surgery Partners, Inc. (SGRY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.34B | 1.77B | 1.83B | 1.86B | 2.23B | 2.54B | 2.74B | 3.11B | 3.31B | 3.34B |
Revenue Growth % | 17.09% | 32.08% | 3.38% | 1.57% | 19.62% | 14.12% | 8.03% | 13.52% | 6.24% | 5.38% |
Cost of Goods Sold | 1.01B | 1.36B | 1.41B | 1.48B | 1.73B | 1.96B | 2.1B | 2.37B | 2.54B | 2.58B |
COGS % of Revenue | 75.59% | 76.85% | 76.86% | 79.58% | 77.92% | 77.36% | 76.4% | 76.06% | 76.88% | - |
Gross Profit | 327.42M▲ 0% | 410.02M▲ 25.2% | 423.8M▲ 3.4% | 379.8M▼ 10.4% | 491.4M▲ 29.4% | 574.9M▲ 17.0% | 647.5M▲ 12.6% | 745.6M▲ 15.2% | 765M▲ 2.6% | 763.3M▲ 0% |
Gross Margin % | 24.41% | 23.15% | 23.14% | 20.42% | 22.08% | 22.64% | 23.6% | 23.94% | 23.12% | 22.83% |
Gross Profit Growth % | 0.98% | 25.23% | 3.36% | -10.38% | 29.38% | 16.99% | 12.63% | 15.15% | 2.6% | - |
Operating Expenses | 156.37M | 157.23M | 187.9M | 196.8M | 189.2M | 229.7M | 319.5M | 396.8M | 375.5M | 416.1M |
OpEx % of Revenue | 11.66% | 8.88% | 10.26% | 10.58% | 8.5% | 9.05% | 11.65% | 12.74% | 11.35% | - |
Selling, General & Admin | 75.95M | 93.56M | 88.6M | 97.1M | 104M | 102.2M | 120.9M | 138.7M | 522.7M | 627.3M |
SG&A % of Revenue | 5.66% | 5.28% | 4.84% | 5.22% | 4.67% | 4.02% | 4.41% | 4.45% | 15.8% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 25.33M | 63.67M | 99.3M | 99.7M | 85.2M | 127.5M | 198.6M | 258.1M | -147.2M | -1000K |
Operating Income | 158.23M▲ 0% | 77.84M▼ 50.8% | 235.9M▲ 203.1% | 183M▼ 22.4% | 302.2M▲ 65.1% | 345.2M▲ 14.2% | 328M▼ 5.0% | 348.8M▲ 6.3% | 389.5M▲ 11.7% | 393.4M▲ 0% |
Operating Margin % | 11.8% | 4.39% | 12.88% | 9.84% | 13.58% | 13.59% | 11.96% | 11.2% | 11.77% | 11.77% |
Operating Income Growth % | -19.47% | -50.81% | 203.07% | -22.42% | 65.14% | 14.23% | -4.98% | 6.34% | 11.67% | - |
EBITDA | 210.16M | 145.28M | 312.4M | 277.8M | 401M | 460M | 446.1M | 501.4M | 565.5M | 571.6M |
EBITDA Margin % | 15.67% | 8.2% | 17.06% | 14.93% | 18.02% | 18.12% | 16.26% | 16.1% | 17.09% | 17.1% |
EBITDA Growth % | -10.96% | -30.87% | 115.04% | -11.08% | 44.35% | 14.71% | -3.02% | 12.4% | 12.78% | 16.68% |
D&A (Non-Cash Add-back) | 51.93M | 67.44M | 76.5M | 94.8M | 98.8M | 114.8M | 118.1M | 152.6M | 176M | 178.2M |
EBIT | 199.96M | 77.8M | 233.5M | 183M | 302.2M | 345.2M | 328M | 348.8M | 389.5M | 712.8M |
Net Interest Income | 0 | -147M | -178.9M | -201.8M | -221M | -234.9M | -193M | -201.7M | -272.6M | -595.6M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 117.67M | 147M | 178.9M | 201.8M | 221M | 234.9M | 193M | 201.7M | 272.6M | 526.5M |
Other Income/Expense | -75.95M | -147M | -181.3M | -201.8M | -221M | -234.9M | -193M | -201.7M | -272.6M | -210.4M |
Pretax Income | 82.29M▲ 0% | -69.17M▼ 184.1% | 54.6M▲ 178.9% | -18.8M▼ 134.4% | 81.2M▲ 531.9% | 110.3M▲ 35.8% | 135M▲ 22.4% | 147.1M▲ 9.0% | 116.9M▼ 20.5% | 113.9M▲ 0% |
Pretax Margin % | 6.14% | -3.9% | 2.98% | -1.01% | 3.65% | 4.34% | 4.92% | 4.72% | 3.53% | 3.41% |
Income Tax | 53.55M | 26.46M | 9.5M | -20.1M | 10.5M | 23.3M | -300K | 134.6M | 18M | 19.2M |
Effective Tax Rate % | 65.08% | -38.26% | 17.4% | 106.91% | 12.93% | 21.12% | -0.22% | 91.5% | 15.4% | 16.86% |
Net Income | -52.98M▲ 0% | -205.71M▼ 288.2% | -74.8M▲ 63.6% | -116.1M▼ 55.2% | -70.9M▲ 38.9% | -54.6M▲ 23.0% | -11.9M▲ 78.2% | -168.1M▼ 1312.6% | -77.9M▲ 53.7% | -76.1M▲ 0% |
Net Margin % | -3.95% | -11.61% | -4.08% | -6.24% | -3.19% | -2.15% | -0.43% | -5.4% | -2.35% | -2.28% |
Net Income Growth % | -660.51% | -288.23% | 63.64% | -55.21% | 38.93% | 22.99% | 78.21% | -1312.61% | 53.66% | 60.65% |
Net Income (Continuing) | 28.74M | -95.6M | 45.1M | 1.3M | 70.7M | 87M | 135.3M | 12.5M | 98.9M | 63.3M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 681.88M | 694.3M | 1.01B | 1.07B | 1.21B | 1.28B | 1.37B | 1.85B | 1.81B | 1.79B |
EPS (Diluted) | -1.08▲ 0% | -4.28▼ 296.3% | 0.95▲ 122.2% | -3.19▼ 435.8% | -1.12▲ 64.9% | -0.59▲ 47.3% | -0.09▲ 83.9% | -1.33▼ 1304.4% | -0.61▲ 54.1% | -0.59▲ 0% |
EPS Growth % | -640% | -296.3% | 122.2% | -435.79% | 64.89% | 47.32% | 83.95% | -1304.44% | 54.14% | 61.46% |
EPS (Basic) | -1.09 | -4.28 | 0.95 | -3.19 | -1.12 | -0.59 | -0.09 | -1.33 | -0.61 | - |
Diluted Shares Outstanding | 49M | 48.03M | 48.28M | 48.78M | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M | 128.37M |
Basic Shares Outstanding | 48.69M | 48.03M | 48.28M | 48.78M | 72.43M | 91.95M | 125.61M | 126.12M | 127.21M | 128.37M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SGRY Balance Sheet
Surgery Partners, Inc. (SGRY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 563.23M | 588.32M | 525.5M | 801.5M | 946.1M | 921M | 895M | 1.12B | 1.15B | 1.08B |
Cash & Short-Term Investments | 174.91M | 184.31M | 92.7M | 317.9M | 389.9M | 282.9M | 195.9M | 269.5M | 239.9M | 182.3M |
Cash Only | 174.91M | 184.31M | 92.7M | 317.9M | 389.9M | 282.9M | 195.9M | 269.5M | 239.9M | 182.3M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 295.62M | 316.14M | 326.9M | 382.2M | 430.2M | 456.3M | 496.4M | 579.1M | 602.2M | 603.4M |
Days Sales Outstanding | 80.45 | 65.14 | 65.15 | 75 | 70.57 | 65.59 | 66.05 | 67.87 | 66.43 | 64.08 |
Inventory | 44.95M | 43.36M | 46.3M | 56.4M | 61.1M | 71.4M | 75.2M | 88.4M | 96.6M | 100.5M |
Days Inventory Outstanding | 16.18 | 11.63 | 12.01 | 13.91 | 12.86 | 13.27 | 13.1 | 13.62 | 13.86 | 13.32 |
Other Current Assets | 30.9M | 28.28M | 41.8M | 27.4M | 39.3M | 79M | 96.5M | 182.4M | 170.9M | 157.5M |
Total Non-Current Assets | 4.06B | 4.09B | 4.49B | 4.61B | 5.17B | 5.76B | 5.98B | 6.77B | 7.09B | 6.96B |
Property, Plant & Equipment | 398.54M | 426.29M | 821M | 854.7M | 953.8M | 1.16B | 1.22B | 1.38B | 1.44B | 1.42B |
Fixed Asset Turnover | 3.37x | 4.16x | 2.23x | 2.18x | 2.33x | 2.20x | 2.24x | 2.25x | 2.29x | 2.33x |
Goodwill | 3.35B | 3.38B | 3.4B | 3.47B | 3.91B | 4.14B | 4.33B | 5.07B | 5.19B | 0 |
Intangible Assets | 58.91M | 54.29M | 47.3M | 46.9M | 43.7M | 42.3M | 54.8M | 45.7M | 41M | 5.25B |
Long-Term Investments | 74.28M | 78.48M | 93.2M | 90.3M | 88.7M | 190.3M | 184.1M | 215.4M | 234M | 909M |
Other Non-Current Assets | 48.66M | 36.85M | 30.8M | 27M | 59.1M | 144.2M | 103.3M | 57.5M | 56.8M | 72.8M |
Total Assets | 4.62B▲ 0% | 4.68B▲ 1.2% | 5.02B▲ 7.3% | 5.41B▲ 7.9% | 6.12B▲ 13.0% | 6.68B▲ 9.2% | 6.88B▲ 2.9% | 7.89B▲ 14.7% | 8.24B▲ 4.5% | 8.04B▲ 0% |
Asset Turnover | 0.29x | 0.38x | 0.36x | 0.34x | 0.36x | 0.38x | 0.40x | 0.39x | 0.40x | 0.42x |
Asset Growth % | 100.56% | 1.16% | 7.33% | 7.86% | 13.01% | 9.23% | 2.91% | 14.74% | 4.46% | 17.33% |
Total Current Liabilities | 303M | 349.3M | 398.1M | 556.8M | 536.8M | 493.4M | 523M | 624.4M | 615.5M | 581.7M |
Accounts Payable | 84.71M | 83.29M | 96.7M | 100.2M | 124.9M | 151.6M | 171.8M | 208.7M | 208.7M | 168.6M |
Days Payables Outstanding | 30.5 | 22.33 | 25.07 | 24.71 | 26.3 | 28.17 | 29.92 | 32.16 | 29.95 | 25.7 |
Short-Term Debt | 58.73M | 55.6M | 56M | 64.4M | 60.4M | 62.8M | 73.3M | 101.4M | 142M | 142.6M |
Deferred Revenue (Current) | -143.44M | -138.84M | 0 | 109.8M | 64.4M | 3.2M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 19.48M | 135.19M | 22.5M | 38.1M | 47.3M | 49.1M | 23.9M | 24.8M | 199.9M | 193.4M |
Current Ratio | 1.86x | 1.68x | 1.32x | 1.44x | 1.76x | 1.87x | 1.71x | 1.79x | 1.87x | 1.86x |
Quick Ratio | 1.71x | 1.56x | 1.20x | 1.34x | 1.65x | 1.72x | 1.57x | 1.65x | 1.71x | 1.69x |
Cash Conversion Cycle | 66.14 | 54.43 | 52.08 | 64.2 | 57.14 | 50.69 | 49.22 | 49.33 | 50.35 | 51.7 |
Total Non-Current Liabilities | 2.98B | 2.54B | 2.92B | 3.23B | 3.28B | 2.91B | 2.99B | 3.63B | 4.1B | 3.98B |
Long-Term Debt | 2.13B | 2.25B | 2.52B | 2.79B | 2.88B | 2.56B | 2.7B | 3.27B | 2.71B | 2.73B |
Capital Lease Obligations | 121.63M | 166.34M | 283.1M | 300.9M | 315.6M | 271.4M | 248.9M | 292.1M | 1.18B | 3.73B |
Deferred Tax Liabilities | 28.38M | 52.28M | 0 | 0 | 0 | 0 | 0 | 39.2M | 175.7M | 307.8M |
Other Non-Current Liabilities | 100.85M | 121.49M | 113.6M | 139.7M | 87M | 75.4M | 41.1M | 30.2M | 41.2M | 41.6M |
Total Liabilities | 4.62B | 4.68B | 3.32B | 3.79B | 3.82B | 3.4B | 3.51B | 4.25B | 4.72B | 4.56B |
Total Debt | 2.19B | 2.48B | 2.9B | 3.2B | 3.29B | 2.93B | 3.06B | 3.7B | 4.02B | 4.03B |
Net Debt | 2.01B | 2.29B | 2.81B | 2.88B | 2.9B | 2.65B | 2.87B | 3.43B | 3.78B | 3.85B |
Debt / Equity | 1.64x | 2.25x | 1.71x | 1.97x | 1.43x | 0.89x | 0.91x | 1.02x | 1.14x | 1.16x |
Debt / EBITDA | 10.42x | 17.04x | 9.29x | 11.51x | 8.22x | 6.37x | 6.86x | 7.39x | 7.12x | 7.05x |
Net Debt / EBITDA | 9.58x | 15.78x | 8.99x | 10.36x | 7.24x | 5.75x | 6.42x | 6.85x | 6.69x | 6.73x |
Interest Coverage | 1.70x | 0.53x | 1.31x | 0.91x | 1.37x | 1.47x | 1.70x | 1.73x | 1.43x | 1.35x |
Total Equity | 1.34B▲ 0% | 1.1B▼ 17.8% | 1.7B▲ 54.6% | 1.62B▼ 4.5% | 2.3B▲ 41.7% | 3.28B▲ 42.7% | 3.36B▲ 2.4% | 3.64B▲ 8.1% | 3.53B▼ 3.0% | 3.48B▲ 0% |
Equity Growth % | 311.68% | -17.78% | 54.64% | -4.47% | 41.67% | 42.75% | 2.41% | 8.13% | -2.98% | -6.87% |
Book Value per Share | 27.28 | 22.88 | 35.20 | 33.28 | 31.75 | 35.70 | 26.76 | 28.82 | 27.72 | 27.12 |
Total Shareholders' Equity | 654.73M | 404.64M | 691.8M | 550.1M | 1.09B | 2B | 1.99B | 1.79B | 1.71B | 1.69B |
Common Stock | 487K | 489K | 500K | 500K | 900K | 1.3M | 1.3M | 1.3M | 1.3M | 1.3M |
Retained Earnings | -41.32M | -247.02M | -315.7M | -431.8M | -502.7M | -557.3M | -569.2M | -737.3M | -815.2M | -851.1M |
Treasury Stock | 0 | 33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -19.68M | -22.45M | -50.7M | -61M | -31.5M | 76.2M | 57.5M | 4.8M | -13.8M | -10.5M |
Minority Interest | 681.88M | 694.3M | 1.01B | 1.07B | 1.21B | 1.28B | 1.37B | 1.85B | 1.81B | 1.79B |
SGRY Cash Flow Statement
Surgery Partners, Inc. (SGRY) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 120.94M | 144.6M | 129.5M | 246.9M | 87.1M | 158.8M | 293.8M | 300.1M | 274.3M | 280M |
Operating CF Margin % | 9.02% | 8.16% | 7.07% | 13.27% | 3.91% | 6.25% | 10.71% | 9.64% | 8.29% | - |
Operating CF Growth % | -3.43% | 19.56% | -10.44% | 90.66% | -64.72% | 82.32% | 85.01% | 2.14% | -8.6% | 114.23% |
Net Income | -52.98M | -95.63M | 45.1M | 1.3M | 70.7M | 87M | 135.3M | 12.5M | 98.9M | -76.1M |
Depreciation & Amortization | 51.93M | 67.44M | 76.5M | 94.8M | 98.8M | 114.8M | 118.1M | 152.6M | 176M | 78M |
Stock-Based Compensation | 5.6M | 9.34M | 10.2M | 13.2M | 17.4M | 18.4M | 17.7M | 33.3M | 14.8M | 8.4M |
Deferred Taxes | 6.88M | 25.27M | 8.5M | -21.9M | 8.9M | 21.9M | -1.7M | 131.5M | 16.7M | 5.1M |
Other Non-Cash Items | 28.11M | 105.01M | 58M | 214.8M | 40.4M | 19M | 86.7M | 89.1M | 78.3M | 252.6M |
Working Capital Changes | 84.99M | 33.16M | -68.8M | -55.3M | -149.1M | -102.3M | -62.3M | -118.9M | -110.4M | -53.5M |
Change in Receivables | -60.62M | -22.82M | -23.5M | -46.6M | -32.1M | -35.3M | -47.2M | -72.1M | -53.8M | -58.6M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -783.45M | -128.86M | -85.2M | -88.4M | -331.7M | -307.9M | -225.6M | -488.5M | -246.6M | -183.6M |
Capital Expenditures | -29.6M | -39.8M | -73.6M | -42.9M | -57.6M | -80.6M | -88.8M | -90.4M | -78.7M | -72M |
CapEx % of Revenue | 2.21% | 2.25% | 4.02% | 2.31% | 2.59% | 3.17% | 3.24% | 2.9% | 2.38% | 2.15% |
Acquisitions | -755.1M | -87.6M | -11.4M | -104.6M | -280.4M | -228.7M | -128.9M | -378.8M | -162.1M | -118.5M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 1.25M | -1.46M | -200K | 59.1M | 6.3M | 1.4M | -7.9M | -22.2M | 7.5M | 6.8M |
Cash from Financing | 767.72M | -6.3M | -135.9M | 66.7M | 316.3M | 42.1M | -155.2M | 262M | -57.3M | -143.4M |
Debt Issued (Net) | 565.13M | 125.1M | -1.7M | 213.1M | -43.8M | -644.2M | 19.5M | 450.4M | 158.7M | 66M |
Equity Issued (Net) | -2M | -2M | 0 | 0 | 581.8M | 882.9M | 0 | 0 | 0 | 0 |
Dividends Paid | -1.32M | -7.8M | 0 | 0 | -5.1M | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -2M | -2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 205.91M | -121.6M | -134.2M | -146.4M | -216.6M | -196.6M | -174.7M | -188.4M | -216M | -209.4M |
Net Change in Cash | 11.77M▲ 0% | 9.39M▼ 20.2% | -91.6M▼ 1075.1% | 225.2M▲ 345.9% | 71.7M▼ 68.2% | -107M▼ 249.2% | -87M▲ 18.7% | 73.6M▲ 184.6% | -29.6M▼ 140.2% | -47M▲ 0% |
Free Cash Flow | 91.34M▲ 0% | 104.8M▲ 14.7% | 55.9M▼ 46.7% | 204M▲ 264.9% | 29.5M▼ 85.5% | 78.2M▲ 165.1% | 205M▲ 162.1% | 209.7M▲ 2.3% | 195.6M▼ 6.7% | 208M▲ 0% |
FCF Margin % | 6.81% | 5.92% | 3.05% | 10.97% | 1.33% | 3.08% | 7.47% | 6.73% | 5.91% | 6.22% |
FCF Growth % | 6.05% | 14.73% | -46.66% | 264.94% | -85.54% | 165.08% | 162.15% | 2.29% | -6.72% | 20.02% |
FCF per Share | 1.86 | 2.18 | 1.16 | 4.18 | 0.41 | 0.85 | 1.63 | 1.66 | 1.54 | 1.62 |
FCF Conversion (FCF/Net Income) | -2.28x | -0.70x | -1.73x | -2.13x | -1.23x | -2.91x | -24.69x | -1.79x | -3.52x | -2.73x |
Interest Paid | 0 | 145.4M | 180.3M | 203.6M | 194.3M | 218.7M | 169.6M | 199.7M | 0 | 0 |
Taxes Paid | 0 | 2.2M | 1.6M | 1.7M | 1.5M | 1.8M | 1.4M | 1.6M | 0 | 0 |
SGRY Key Ratios
Surgery Partners, Inc. (SGRY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -6.38% | -16.89% | -5.35% | -6.99% | -3.61% | -1.96% | -0.36% | -4.8% | -2.18% | -2.15% |
Return on Invested Capital (ROIC) | 4.65% | 1.73% | 4.48% | 3.05% | 4.67% | 4.65% | 4.05% | 3.93% | 4.06% | 4.06% |
Gross Margin | 24.41% | 23.15% | 23.14% | 20.42% | 22.08% | 22.64% | 23.6% | 23.94% | 23.12% | 22.83% |
Net Margin | -3.95% | -11.61% | -4.08% | -6.24% | -3.19% | -2.15% | -0.43% | -5.4% | -2.35% | -2.28% |
Debt / Equity | 1.64x | 2.25x | 1.71x | 1.97x | 1.43x | 0.89x | 0.91x | 1.02x | 1.14x | 1.16x |
Interest Coverage | 1.70x | 0.53x | 1.31x | 0.91x | 1.37x | 1.47x | 1.70x | 1.73x | 1.43x | 1.35x |
FCF Conversion | -2.28x | -0.70x | -1.73x | -2.13x | -1.23x | -2.91x | -24.69x | -1.79x | -3.52x | -2.73x |
Revenue Growth | 17.09% | 32.08% | 3.38% | 1.57% | 19.62% | 14.12% | 8.03% | 13.52% | 6.24% | 5.38% |
Related:SGRY Dividend History·SGRY Revenue History·SGRY Price History·SGRY P/E History·SGRY Financial Ratios·SGRY Institutional Holders
SGRY SEC Filings & Documents
Surgery Partners, Inc. (SGRY) SEC filings — annual & quarterly reports (10-K, 10-Q)
SGRY Frequently Asked Questions
Surgery Partners, Inc. (SGRY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Surgery Partners, Inc. (SGRY) reported $3.34B in revenue for fiscal year 2025. This represents a 1075% increase from $284.6M in 2013.
Surgery Partners, Inc. (SGRY) grew revenue by 6.2% over the past year. This is steady growth.
Surgery Partners, Inc. (SGRY) reported a net loss of $76.1M for fiscal year 2025.
Dividend & Returns
Surgery Partners, Inc. (SGRY) has a return on equity (ROE) of -2.2%. Negative ROE indicates the company is unprofitable.
Surgery Partners, Inc. (SGRY) generated $208.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.